By a News Reporter-Staff News Editor at Politics& Government Week A patent application by the inventors Verma, Daya; Teng, Yue; Singh, Rajinder; Thompson, Dan, filed on October 22, 2013, was made available online on February 20, 2014, according to news reporting originating from Washington, D.C., by VerticalNews correspondents. This patent applic
Verona Pharma plc Proposed Placing and Subscription of New Ordinary Shares to raise 13.0 million Proposed Open Offer of New Ordinary Shares to raise up to a further 1.0 million and Notice of General Meeting 6 March 2014, London- Verona Pharma plc, the drug development company focused on "first-in-class" medicines to treat respiratory diseases,
Acadia Pharmaceuticals Inc. announced that it intends to offer and sell, subject to market and other conditions, $150,000,000 of shares of its common stock in an underwritten public offering. Acadia reported that Jefferies and J.P. Morgan Securities are acting as the joint book-running managers for the offering. Cowen and Company is acting as the l
ActiGraph s new Study Admin Portal, in conjunction with the company s newest generation of Bluetooth Smart wireless actigraphy monitors, solves many of the logistical challenges faced by pharmaceutical companies and clinical research organizations seeking to enhance the quality of their trial data through the collection of objective physical.
Alcobra Ltd., an emerging biopharmaceutical company primarily focused on the development and commercialization of its proprietary drug candidate Metadoxine Extended Release to treat cognitive dysfunctions, such as Attention Deficit Hyperactivity Disorder and Fragile X Syndrome, announced today that the US. Food and Drug Administration has cleared
Alkermes plc today announced the initiation of the pivotal clinical development program for ALKS 5461, a once-daily, oral investigational medicine with a novel mechanism of action for the adjunctive treatment of major depressive disorder. Alkermes expects to use safety and efficacy data from the FORWARD studies as the basis for a New Drug Applicati
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that the previously announced acquisition of Merck s wholly owned subsidiary Sirna Therapeutics, Inc. has closed, following the expiration of the Hart-Scott-Rodino waiting period. On January 10, 2014, Alnylam entered into a stock purchase agreement with Merck pur
ANI Pharmaceuticals, Inc. announced today that its President and Chief Executive Officer, Arthur S. Przybyl, is scheduled to present at the 26th Annual ROTH Conference at the Ritz-Carlton at Laguna Niguel, California on Monday, March 10, 2014 at 11:30 a.m. Pacific Time. Mr. Przybyl's presentation will be webcast live at http://wsw.com/webcast/roth2
March 05 The bankrupt entity KV Pharmaceutical Co. has proposed to pay $12.8 million to settle allegations that it misled investors and artificially inflated the value of its stock, a law firm involved in the case announced Wednesday. The suit alleges that former officers of the Bridgeton- based drugmaker made false and misleading statements betw
BellBrook Labs has partnered with Lucerna-Chem for distribution of their Transcreener HTS Assay products in Switzerland as of January 2014. The partnership leverages Lucerna-Chem s existing supply arrangements with pharma and biotech companies in Basel and key academic centers focused on drug discovery. BellBrook Labs is dedicated to accelera
INGELHEIM, Germany and RIDGEFIELD, Conn., March 6, 2014/ PRNewswire/ Today Boehringer Ingelheim announced results from STARTVerso 4 in patients with HCV/HIV co-infection. Hepatitis C viral cure 12 weeks after the conclusion of treatment was achieved by 72% of all patients in the trial. "The SVR12 data from STARTVerso 4 are encouraging, esp
Brazl is an emerging markets that drugmakers have gravitated in recent years, hoping for returns that outpace the slower growth at home. That is the phase Eli Lilly is in a packaging operation in So Paulo. Sanofi has big operations there and even Russia s Biocad would build a new $40 million facility in southern Brazilian state of Paran to make
Catalyst Pharmaceutical Partners, Inc., today announced that the Company will be presenting at the 26 th Annual ROTH Conference, in California. Catalyst Pharmaceutical Partners, Inc. is a specialty pharmaceutical company focused on the development and commercialization of prescription drugs targeting rare neuromuscular and neurological diseases,.
LONDON and WILMINGTON, North Carolina, March 6, 2014/ PRNewswire/ Chiltern International Limited, a global contract research organization, announced that Chiltern has been recognized with a CRO Leadership Award in all five categories: Quality, Reliability, Productivity, Innovation and Regulatory. The winners should be proud of these awards becaus
Acorn Applications, LLC, a developer of cloud-based analytic clinical research solutions, announced today that Clintrax Global, a clinical trial contract negotiation company, has selected TrialCTA as its new global contract management software solution. TrialCTA, Acorn Applications' lead product, is a cloud-based Software-as-a-Service application..
Dublin- Research and Markets has announced the addition of the "Commercial Potential of the Forthcoming US Biosimilars Market" report to their offering. The report assesses physicians' willingness to prescribe biosimilars in the United States. The objective of this research was to conduct a highly qualitative analysis of a representative sample of
Designed to address the rapidly changing requirements of pharmaceutical development and manufacturing, PCMM aims to meet the industry s needs for continuous processing in a flexible, self-contained manufacturing space. We believe our presence at Interphex, with a show POD and GEA Pharma Systems equipment, provides a great opportunity to demon
Corium International, Inc., a commercial stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal pharmaceutical products, announced that it has filed a registration statement on Form S-1 with the Securities and Exchange Commission for a proposed initial public offering of its common...
Covidien plc, a global provider of healthcare products and patient monitoring and respiratory care devices, announced its Puritan Bennett 980 ventilator has received European Economic Area CE Mark approval. "We are excited to introduce our next-generation acute ventilation platform, the Puritan Bennett 980 ventilator," said Cristiano Franzi, presi
Increased collaboration across industry, with three quarters partnering and 20% having merged or acquired an asset in the last year alone Anticancer drugs and antibiotics seen as major disease targets Combination drugs and personalised medicine are the most important novel focus areas With nanotechnology and drug devices featuring prominently...
- Dainippon Sumitomo Pharma Co. said Thursday it has set up a joint venture in Kobe with a venture company to produce medicine using induced pluripotent stem cells for the treatment of eye diseases. Dainippon Sumitomo and Healios K.K. established the fifty-fifty joint venture, SighRegen K.K., capitalized at 50 million yen, in Kobe's artificial Port
DARA BioSciences, Inc., an oncology supportive care pharmaceutical company dedicated to providing health care professionals a synergistic portfolio of medicines to help cancer patients adhere to their therapy and manage side effects arising from their cancer treatment, today announced that David J. Drutz, M.D., DARA's Chief Executive Officer and Ch
Diasome Pharmaceuticals, Inc. has received notice from its licensor, SDG, Inc., that SDG has received a notice of allowance for its novel weight loss nanotechnology patent application. Diasome Pharmaceuticals has received a worldwide, exclusive license to this technology from SDG, along with technology rights to SDG s platform of hepatic targete
"Inhibiting faster adoption of social media in drug development has been a lack of regulatory guidance, particularly from the U.S. Food and Drug Administration, and concerns about the impact of social media on research integrity," said Ken Getz, associate professor and director of sponsored research at Tufts CSDD. The Tufts Center for the Study of
Bharat Book Bureau presents Effective Pharma KAM Teams- the essential factors driving performance. This new report provides everyone involved with building running or implementing KAM strategy with a complete understanding of the issues which are shaping the operating environment and the essential qualities necessary in a competent KAM set up....